Details of the Drug Combination

General Information of Drug Combination (ID: DCS7SA7)

Drug Combination Name

Arfolitixorin TEM

Indication

Disease Entry	Status	REF
Large cell lung carcinoma	Investigative	[1]

Component Drugs

Arfolitixorin DMIXMYK

TEM DMLNFWU

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: NCI-H460

Zero Interaction Potency (ZIP) Score: 3.11

Bliss Independence Score: 4.26

Loewe Additivity Score: 0.71

LHighest Single Agent (HSA) Score: 3.1

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCRJT9G	HCT116	Investigative	[1]
Adenocarcinoma	DC7FGX9	SW-620	Investigative	[1]
Minimally invasive lung adenocarcinoma	DCLUYI5	NCI-H322M	Investigative	[1]
Prostate carcinoma	DCZSVYG	PC-3	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)